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BRIEF TRIAL SUMMARY  
Background. Treatment with intravenous ferric carboxymaltose (FCM) showed to 
improve symptoms, functional capacity, and quality of life in patients with heart failure 
(HF) and iron deficiency (ID). However, the underlying mechanisms for these 
beneficial effects remain undetermined. The aim of this study is to quantify cardiac 
magnetic resonance (CMR) changes in myocardial iron content after administration of 
intravenous FCM in patients with HF and ID and contrast them with parameters of HF 
severity.  
Methods. This is a multicenter, double-blind, randomized study. Fifty patients with 
stable symptomatic HF, left ventricular ejection fraction (LVEF) <50%, and ID will be 
randomly assigned 1:1 to receive intravenous FCM or placebo. Intramyocardial iron 
will be evaluated by T2* and T1 mapping CMR sequences before, 7 and 30 days after 
FCM. After 30 days, patients assigned to placebo will receive intravenous FCM in case 
of persistent ID. The main endpoint will be changes from baseline in myocardial iron 
content at 7 and 30 days. Secondary endpoints will include the correlation of these 
changes with LVEF, functional capacity, quality of life, and cardiac biomarkers.  
Results. The results of this study will add important knowledge about the effects of 
intravenous FCM on myocardial tissue and cardiac function.  
Conclusions. We hypothesize that short-term (7 and 30 days) myocardial iron content 
changes -evaluated by CMR- after intravenous FCM would correlate with simultaneous 
changes in parameters of HF severity. The study is registered at http://clinicaltrials.gov 
(NCT03398681). 
 
Key words: Heart failure; Iron deficiency; Cardiac magnetic resonance; Ferric 
carboxymaltose; Myocardial iron. 













ACEI: angiotensin converting enzyme inhibitors 
ARB: angiotensin receptor blockers 
CA125: carbohydrate antigen 125 
CMR: cardiac magnetic resonance 
eGFR: estimated glomerular filtration rate  
FCM: ferric carboxymaltose  
HF: heart failure  
HFrEF: heart failure with reduced ejection fraction 
hsTnT: high-sensitivity troponin T 
ID: iron deficiency 
KCCQ: Kansas City Cardiomyopathy Questionnaire 
LVEF: left ventricle ejection fraction  
NGAL: neutrophil gelatinase-associated lipocalin 
NT-proBNP: amino-terminal pro-brain natriuretic peptide 
sTfR: soluble transferrin receptor  
TSAT: transferrin saturation  
6MWT: 6-minutes walking test 
 
 












Iron deficiency (ID) is a common finding in patients with heart failure (HF). It is 
usually  associated, even in the absence of anemia, with decrease in functional capacity, 
quality of life, and with increased risk of mortality and readmission.1-7 Treatment with 
intravenous ferric carboxymaltose (FCM) in patients with HF and ID has shown 
improving symptoms, functional capacity, quality of life, and decrease hospitalizations 
under an acceptable safety profile.8,9 Such benefit has been consistent in patients with 
and without anemia,10,11 suggesting additional pathophysiological pathways beside 
anemia resolution. In addition, recent studies suggested that myocardial ID could play a 
direct role in the pathogenesis and progression of HF.12-14 
Despite the fact that T2* cardiac magnetic resonance (CMR) sequence has 
shown to provide a reliable assessment of myocardial iron content15-18 newer 
techniques, such as T1 mapping, have emerged as an alternative tool for myocardial 
iron assessment.19 Changes in myocardial T1 mapping are more linear and have fewer 
artifacts than with T2* sequence, which translated into a more reproducible and 
sensitive technique.20 Thus, in this work we aim to evaluate the utility of T1 mapping 
for detecting myocardial iron changes after intravenous iron administration. In a recent 
pilot study, our group reported an association between intravenous FCM administration 
and myocardial iron repletion assessed by T2* CMR. Interestingly, myocardial iron 
changes were strongly related to an improve in left ventricular ejection fraction 
(LVEF).21 
We sought to determine that short-term (7 and 30-d) myocardial iron content 
changes -evaluated by T1* CMR- after intravenous FCM would correlate with 
simultaneous changes in parameters of HF severity. 
 












Overall study design 
This is a multicenter, double-blind, randomized, and placebo-controlled study 
aimed to test the effect of intravenous FCM [Ferinject®, Vifor Pharma (Glattbrugg, 
Switzerland)] on myocardial iron content assessed by CMR in five academic centers in 
Spain (Hospital Clínico Universitario de Valencia, Hospital de Manises, Hospital 
General Universitari de Castelló, Hospital Universitario y Politécnico La Fe, and 
Consorci Hospital General Universitari de Valencia). After signing the informed 
consent, patients will be randomized 1:1 to receive FCM or placebo. Intramyocardial 
iron will be evaluated before its administration, at 7 and 30 days. At 30-day, patients 
assigned to placebo will receive FCM if ID persists (Figure 1). 
The study will be carried out in accordance with the principles of the Declaration 
of Helsinki (1996) and the Good Clinical Practice of the International Conference on 
Harmonization. The study protocol was approved by Agencia Española del 
Medicamento y Productos sanitarios (AEMPS) on 6th December 2016 and by Comité 
Ético de Investigación Clínica (CEIC) del Hospital Clínico Universitario de Valencia on 
26th January 2017, with an amendment on 22nd June 2017. CMR studies will be 
performed by ERESA (Valencia), and laboratory parameters will be analyzed in local 
labs. The study is registered at http://clinicaltrials.gov (NCT03398681). 
 
Study population 
 Eligible patients are those with stable chronic HF (NYHA II-III), LVEF <50%, 
and ID, the latter defined as serum ferritin <100μg/L or 100-299μg/L with transferrin 
saturation (TSAT) <20% and hemoglobin <15g/dL. All patients must meet all inclusion 
criteria and none exclusion criteria (Table 1). 













Patients will be randomly allocated into 1:1 ratio to receive FCM or placebo by 
means of a web-based computer-generated block sequence. Investigators and patients 
will be blinded to treatment allocations. 
 
Study procedures 
Summary of study procedures are detailed in Table 2. 
 
Cardiac magnetic resonance 
CMR data will be blindly acquired and quantified offline by two experienced 
cardiologists (M.P.L.L. and J.V.M., both with 15 years’ experience in CMR imaging) 
on a 1.5 Tesla MR scanner (Essenza y Avanto, Siemens, Erlangen, Germany). The three 
consecutive CMR studies of each patient will be analyzed by the same operator. No 
contrast media is used. All images are obtained with electrocardiographic gating and 
breath-holding. 
Cine images are acquired at rest in short axis views every 1 cm with steady-state 
free precession imaging sequences (time resolution: 37ms; voxel size: 1.7x1.7x7mm). 
Right and left ventricle (LV) ejection fraction (%), LV end-diastolic an end-systolic 
volume index (mL/m2), and LV mass (g/m2) are calculated by semiautomatic 
planimetry of endocardial and epicardial borders in short-axis views cine images. 
The basic T2* pulse sequence is a breath hold, multiecho gradient echo T2* 
sequence (voxel size: 1.6x1.6x8 mm) with 8 echo times from 2.65 to 21ms, in mid-
ventricular short axis. For T2* analysis, a region of interest (ROI) is chosen in the mid-
left ventricular septum. The mean signal intensities of ROI are measured in the series of 











increasing TE images to give an exponential decay curve. The monoexponential decay 
model and the nonlinear curve fitting algorithm are used to fit the curve to obtain T2* 
measurement. 
T1 mapping is performed with MOLLI sequences with motion correction (voxel 
size: 1.5x1.5x7mm) in three short axes (basal, medial and apical). After T1-maps are 
generated, a ROI is chosen in the mid-left ventricular septum in the three-short axis and 
the average T1 values are calculated.  
Details of the CMR sequences used are described in Appendix 3. All 
measurements were made on the platform Syngo MR C15, Siemens. The same protocol 
will be repeated at 7 and 30 days. 
 
Six-minutes walking test (6MWT) 
The 6MWT is performed in a place well equipped for cardiopulmonary 
resuscitation. Subjects are advised not to have undertaken vigorous exercise within the 
previous two hours and instructed to cover the maximum distance possible in six 
minutes, at a self-graded walking speed. Pausing to rest will be allowed when needed.  
 
Kansas City Cardiomyopathy Questionnaire (KCCQ) 
The KCCQ it is a self-administered instrument designed to evaluate health-
related quality of life in chronic HF patients. It is composed of 23 items (15 questions) 
that form seven domains: physical limitations, symptoms (frequency, severity and 
change over time), self-efficacy and knowledge, social interference and quality of life. It 
is scored by assigning each response 1 to 5, 6 or 7 points, being 1 de lowest 
punctuation. The sum of these items is subsequently transformed to a scale of 0 to 100 











points (Appendix 2).22 The Spanish version of the KCCQ23 will be filled-in by patients 
with the support of trained nurses. 
 
Biomarkers 
The results from lab data will be reviewed and signed by the investigator who 
will record in the case report form whether they are normal, abnormal, and clinically 
significant. The following parameters will be assessed at baseline, 7, and 30 days: a) 
hematology: hemoglobin, hematocrit, red cell distribution width, mean corpuscular 
volume, and mean corpuscular hemoglobin; b) serum electrolytes: sodium, potassium 
and chloride; c) ID parameters: ferritin, TSAT, soluble transferrin receptor (sTfR), and 
hepcidin; d) renal function parameters: cystatin C, serum creatinine, blood urea 
nitrogen, and estimated glomerular filtration rate (eGFR); e) liver function parameters: 
alanine amino-transferase, and aspartate amino-transferase; and, f) HF-biomarkers: 
carbohydrate antigen 125 (CA125), amino-terminal pro-brain natriuretic peptide (NT-
proBNP), galectin-3, ST-2, and high-sensitivity troponin T (hsTnT). 
 
Clinical visits 
Summary of study procedures performed at each visit are detailed in Table 2. 
Screening and eligibility assessment (visit 0)  
 After signing and dating the informed consent, the study procedures will be 
initiated.  
Follow-up Visits 
Scheduled follow-up visits will be performed at 24 hours, 7 and 30 days after 
randomization. Patients will be censored if they withdraw from the informed consent or 
die.  












Optional visits are permitted. The main reason for each optional visit, and for 
any laboratory or procedure additionally performed must be recorded on the case report 




Eligible patients will be randomized to receive FCM or placebo. 
 
Intravenous ferric carboxymaltose (FCM) 
FCM solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will 
be given as a perfusion of 20 mL (equivalent to 1000 mg of iron) diluted in a sterile 
saline solution [0.9% NaCl] and administered over at least 15 min.  
 
Placebo 
Normal saline [0.9% NaCl] will be administered as per the instructions in the 
placebo-group. Because FCM is a dark-brown solution easily distinguishable, the 
personnel responsible for its preparation and administration will not be involved in any 
study assessments. To ensure that patients will be unaware of the study drug, the 
materials used in drug administration will be covered with aluminum foil or other 
opaque material and the injection site shield from the patient view. 
 
Concomitant drugs 
The indication of other HF-drugs will be done according to the current 
recommendations for clinical practice. 














The main endpoint will be the changes from baseline at 7 and 30 days in 
myocardial iron content assessed by T2* and T1 mapping CMR sequences. The 
statistical comparisons for the primary efficacy objective will test the null hypotheses of 
no differences in changes from baseline in myocardial iron content –as assessed by T2* 
and T1 mapping CMR; the alternative hypotheses will indicate differences in either 
direction. Strictly speaking, the primary objective will be the 30-day evaluation; the 7-
day evaluation will be considered as a co-primary endpoint. 
 
Secondary endpoints 
 - On the entire sample, to correlate these changes with the following clinical 
markers of disease severity a) LVEF, b) functional capacity (6MWT and NYHA class), 
c) quality of life (KCCQ), and d) cardiac biomarkers. 
 - On the sample stratified into three pre-specified subgroups: a) age >70 years 
vs. ≤70 years, b) anemia vs. no anemia (according to WHO criteria), and c) ischemic vs. 
non-ischemic etiology. 
 - On the entire sample, to correlate these changes with blood markers specific to 
iron biology/deficiency (ferritin, TSAT, sTfR, and hepcidin). 
  
Safety endpoints 
Based on previous studies,8,9 a safety surveillance will be specifically focused 
on: a) general disorders and administration site conditions, b) skin and subcutaneous 
tissue disorders, c) nervous system disorders, d) gastro-intestinal disorders, e) vascular 











disorders, f) ear and labyrinth disorders, g) injury, poisoning and procedural 
complications, and, h) cardiac disorders. 
 
Sample size calculation 
The sample size was calculated based on the expected changes in T2*, according 
to the following parameters: 1) two treatment arms; 2) statistical power of the primary 
endpoint of 80%; and 3) alpha error of 0.05. We used repeated measures ANOVA using 
the Lawley-Hotelling test to evaluate the effect of treatment. Based on studies from our 
group,21 we predict a mean difference of 9.25±8.69 in T2* at 30 days after treatment, 
and a correlation of 0.38 between T2* measurements at baseline and 1 month later. The 
correlation of T2* at baseline and 7 days would be 0.40, since we expect the correlation 
to decrease with time. For a desired power of 0.80 and a Type I error of 0.025, we need 
to include 42 participants to detect a mean difference of 9.25 on T2* at 30 days, 
assuming no differences with placebo. Assuming a loss of 10% of patients, we 
increased the sample size to 50 patients (25 patients per arm).  
 
Statistical analysis 
All statistical comparisons will be made under an intention-to-treat principle. 
Continuous variables will be presented as mean (standard deviation) for normally-
distributed variables, and as median (interquartile range) otherwise. Discrete data will 
be expressed as percentages.  
The primary and secondary endpoints will be tested using an ANCOVA-design 
within a framework of linear mixed model. The analysis will include a between (FMC 
vs. placebo) and within comparison (changes at 7 and 30 days). The interaction term 
Tx*visit will be included if the omnibus p-value ≤0.05. The ANCOVA model for the 











primary analysis will include as dependent variable the myocardial T2* CMR values; 
the contrast among treatment groups at 30-d and 7-d will test the primary and co-
primary endpoint respectively. As a pre-specified analysis, no adjustment for multiple 
comparisons will be made. Baseline value of myocardial T2* CMR will be included as 
an obligated covariate. The use of other covariates will be dictated if important 
differences among treatment groups were observed after randomization. Based on the 
normality of residuals a decision about transforming the outcome variable will be made.  
A similar approach will be taken for the secondary endpoints where left and right 
ventricular systolic function, KCCQ, NYHA class, and serum biomarkers will be the 
outcome variables. A two-sided p-value of 0.05 will be considered statistically 
significant for all analyses. Statistical package STATA 15.1 (STATA Statistical 
Software: Release 15.1, College Station, TX, USA) will be used for the analysis. 
 
Current status 
Patient enrollment started in May 2017. On December 31st, 2017, 25 patients 
have been enrolled in the study (50% of the target). Baseline characteristics of these 
patients are described in table 3. 
 
Planned substudies 
Some substudies are planned: a) the correlation of basal T1 mapping and T2* 
with basal ferritin and TSAT; b) correlations of changes in T1 mapping and T2* with 
changes in ferritin and TSAT; c) the effect of FCM on right ventricular function; and, d) 
the effect of FCM on left ventricular tissue Doppler. 












Once the study is finished the changes in T2* and T1 mapping after FCM 
administration at 7 and 30 days will be documented. Furthermore, we will describe 
changes in laboratory data, functional capacity (6MWT, NYHA class), quality of life 
(KCCQ), LVEF, and ventricular diameters and volumes in echocardiography and CMR. 
Finally, we will relate the changes in T2* and T1 mapping with secondary endpoints 
mentioned above. We expect the results available around October 2018.  












The prevalence of ID in chronic HF is approximately 50%, and commonly 
associated with decreased functional capacity and quality of life, and increased risk of 
mortality and readmission, even in the absence of anemia.1-7 Indeed, the administration 
of FCM has shown to reverse these changes within an acceptable safety profile.8,9 
Several studies have demonstrated clinical improvement after intravenous iron 
administration in patients with and without anemia, suggesting that its beneficial effect 
includes additional mechanisms independent of the erythropoietic pathway.10,11  
 
Iron and myocardial function 
Iron plays a crucial role in: 1) oxygen transport, through the production of 
hemoglobin, 2) oxygen storage, through myoglobin, and 3) as a component of the 
mitochondrial respiratory chain involved in energy production.1  
An experimental studies have shown that anemia-deficient iron rats developed 
LV hypertrophy and dilation due to mitochondrial ultrastructural damage.12 Another 
study in non-anemic iron-deficient mice showed that iron content in cardiomyocytes 
and mitochondrial function were restored by iron repletion.13 In humans, a small study 
showed a reduction in the iron content of cardiomyocytes in patients with HF and 
reduced ejection fraction (HFrEF) as compared to controls.14 More recently, Toblli et al, 
in a small randomized trial including 60 patients with HFrEF, ID, and chronic kidney 
disease, showed that iron sucrose administration translated into a significant 6-month 
improvement in LVEF.24 More recently, findings from a cohort of 232 patients 
undergoing renal transplantation showed an increase of LVEF which was particularly 
notorious in those with systolic dysfunction.25 











This preliminary evidence has led us to postulate that myocardial ID may play a 
direct role in the pathogenesis and progression of HF. However, the clinical impact of 
myocardial ID on HF has not been thoroughly evaluated, mainly because of the lack of 
reliable and widely available noninvasive techniques for myocardial iron quantification. 
 
CMR and myocardial iron assessment 
CMR has emerged as a non-invasive accurate technique for evaluation of cardiac 
anatomy, function, and risk stratification.26,27 More recently, this technique has been 
used to assess myocardial iron content.15 T2* CMR sequence has been considered a 
reliable tool for myocardial iron overload assessment.16,17 Nagao et al, in a small case-
control study, found a significant decrease in myocardial iron concentration, assessed by 
T2* CMR, particularly in non-ischemic HF patients.18 Later, these authors also reported 
that T2* CMR was related to an increased risk of adverse outcomes.18 In a pilot study of 
8 patients with HFrEF, our group found that treatment with FCM was associated with 
significant 30-day changes in T2* CMR, and they were associated to marked 
improvement in LVEF.21 Some new CMR techniques, such as T1 mapping, have 
emerged as a potential alternative for myocardial iron quantification.19 We postulate that 
T1 mapping CMR sequence, a more sensitive and reproducible technique,20 could also 
identify myocardial ID and quantify changes in myocardial iron content after FCM 
administration. 
In summary, preliminary evidence suggests that myocardial iron content plays a 
key pathophysiological role in HF. We speculate that with the new CMR sequences we 
will be able to reliably assess changes in myocardial iron content after intravenous iron 
administration, and, thereby, opening new modality of treatments for HF patient’s care. 
In addition, these results will add new insights about the role of iron in the 











physiopathology of the disease. A randomized clinical trial is a necessary step forward 
to advance the knowledge in this area. 
 
Limitations 
There is a possibility that large areas of fibrosis may modify T2* and T1 
measurement irrespective of iron status. As CMR are only performed on 1.5T machines, 
and T1 mapping is performed with MOLLI sequence, the extrapolation of the findings 
to 3T machines or other T1 mapping protocols is unknown. 
Several factors inherent to the study design, such a lower dose (and one time) 
administration of FCM, short trial duration (endpoint assessment at 30 days), the broad 
inclusion criteria (LVEF up to 50%, anemia not required), might reduce the expected 
response to therapy. In addition, the small number of patients leading to inadequate 




We hypothesize that T2* and T1 mapping CMR sequences would be sensitive 
enough to detect changes in myocardial iron content following administration of FCM, 
and that those changes would correlate with surrogates of HF severity. 
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Figure 1. Study design.  
V: visit; HF: heart failure; R: randomization; FCM: ferric carboxymaltose. 
 
 













Figure 1  
 










Table 1. Inclusion and exclusion criteria 
 
Inclusion criteria 
 Outpatients with chronic HF  
 Oder than 18 years 
 NYHA II-III with optimal medical treatment in the last 4 weeks, without dose 
changes of HF treatment in the last 2 weeks (except for diuretics) 
 NT-proBNP >400 pg/mL 
 LVEF <50% in the last 12 months 
 ID, defined as: serum ferritin <100μg/L, or 100-299μg/L if TSAT <20% and 
Hemoglobin <15 g/dL 
 Participants are willing and able to give informed consent for participation in the 
study 
Exclusion criteria 
 Known intolerance to FCM 
 History of acquired iron overload 
 Severe valve disease or cardiac surgery scheduled in the next 30 days 
 ACS, TIA, or ictus in the 3 previous months 
 CABG, major surgery, or cardiac, cerebrovascular or aortic percutaneous 
intervention (diagnostic angiography is allowed) in the 3 previous months 
 Scheduled revascularization in the next 30 days 
 Scheduled CRT device implantation in the next 30 days 
 Active bleeding in the last 30 days 










 Active infection or malignancy 
 Immediate need for transfusion or hemoglobin ≥15g/dL 
 Anemia for reasons other than ID 
 Immunosuppressive therapy or dialysis 
 History of treatment with erythropoietin, intravenous iron, or transfusion in the 
previous 12 weeks 
 Treatment with oral iron at doses >100mg/day in the previous week  
 Contraindications to CMR, including non-compatible pacemakers or defibrillators, 
cochlear implants, cerebral aneurysm clips, claustrophobia, or large body size that 
does not allow the performance of the test. 
 Pregnant or lactating women 
 Subject of childbearing age who is unwilling to use adequate contraceptive 
measures during the study and up to 5 half-lives after the administration of study 
treatment 
 Participation in another trial at the time of inclusion or in the previous 30 days  
 Any disorder that compromises the ability to sign informed consent and/or comply 
with study procedures 
 
HF: heart failure; NYHA: New York Heart Association; NT-proBNP: amino-terminal 
pro-brain natriuretic peptide; LVEF: left ventricle ejection fraction; ID: iron deficiency; 
TSAT: transferrin saturation; FCM: ferric carboxymaltose, ACS: acute coronary 
síndrome; TIA: transient ischemic attack, CABG: coronary artery by-pass surgery, 
CRT: cardiac resincronization therapy, CMR: cardiac magnetic resonance. 
 










Table 2. Study procedures 
 
NYHA: New York Heart Association, MWT: 6-minute walking test; KCCQ: Kansas 













Informed Consent Form X     
Medical History X     
Concomitant 
medications 
X     
Physical examination X X X X X 
Vital signs X X X X X 
Review of inclusion and 
exclusion criteria 
X     
Randomization  X    
Electrocardiogram X   X  
Echocardiography  X   X  
Laboratory tests X  X X  
NYHA functional class X X X X X 
6MWT X  X X  
KCCQ X  X X  
CMR  X  X X  
Adverse clinical events  X X X X 
Changes in treatment  X X X X 










Table 3. Baseline characteristics 
 
Variables n=25 
Demographics and medical history 
Age, years 72.5 (67-78.5) 
Male, n (%) 17 (68.0) 
Hypertension, n (%) 16 (64) 
Dyslipidemia, n (%) 15 (60) 
Diabetes Mellitus, n (%) 12 (48) 
Smoker, n (%) 3 (12.0) 
Former smoker, n (%) 13 (52.0) 
Coronary artery disease, n (%) 9 (36.0) 
Hospital admission for AHF in the last 
year, n (%) 
14 (56.0) 
COPD, n (%) 6 (24.0) 
CKD, n (%) 8 (32.0) 
Stroke, n (%) 5 (20.0) 







Heart rate, bpm 70 (60-79) 
SBP, mmHg 118 (106-130) 
Electrocardiogram and echocardiography 
Atrial fibrillation, n (%) 9 (36.0) 










LVEF, % 40 (34-44) 
Laboratory 
Hemoglobin, g/dL 12 (12.1-13.3) 
Anemia (WHO criteria), n (%) 8 (32.0) 
Transferrin saturation, % 14.9 (11-18.9) 
Ferritin, ng/mL 78 (42-148) 
Absolute iron deficiency, n (%) 14 (56) 
Relative iron deficiency, n (%) 11 (44.0) 
Lymphocyte count, x103 cells/ml 1720 (1210-2130) 
Sodium, mEq/L 140 (139-142) 
Potassium, mEq/L 4.6 (4.3-4.9) 
Urea, mEq/L 62 (50-82) 
Serum creatinine, mg/dl 1.17 (.94-1.57) 
eGFR <60 mg/dL/1.73 m2, n (%) 62 (44-83) 
NT-proBNP, pg/ml,  1690 (1117-2836) 
Medical treatment 
Diuretics, n (%) 23 (92.0) 
Beta-blockers, n (%) 22 (80.0) 
ACEI, n (%) 6 (24.0) 
ARB, n (%) 6 (24.0) 
Sacubitril/Valsartan, n (%) 6 (24.0) 
MRI, n (%) 13 (52.0) 
 
ACEI: angiotensin converting enzyme inhibitors; AHF: acute decompensate heart 
failure; ARB: angiotensin II receptor blockers; CKD: chronic kidney disease; COPD: 










chronic pulmonary obstructive disease; eGFR: estimated glomerular filtration rate; 
LOS: length of stay; LVEF: left ventricular ejection fraction; MI: myocardial infarction; 
MRI: mineralocorticoid receptor inhibitors; NT-proBNP: amino-terminal pro-brain 
natriuretic peptide; NYHA: New York Heart Association; SBP: systolic blood pressure; 
WHO: World Heart Organization. 
WHO criteria for anemia: adult male, hemoglobin 13 g/dL, adult, non-pregnant female, 
hemoglobin 12 g/dL, adult pregnant female, hemoglobin 11 g/dL.  
Absolute iron deficiency: ferritin <100 ng/mL 
Relative iron deficiency: ferritin 100-299 ng/mL and transferrin saturation <20%.  
Values expressed as median (interquartile range); categorical variables are presented as 
percentages. 
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